Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S1 is a proprietary botanical cannabis formulation developed by Tikun Olam USA, specifically designed for the treatment of sleep disorders and anxiety. As a standardized cannabis-based product, it is formulated to contain a specific profile of cannabinoids and terpenes intended to provide sedative and anxiolytic effects. The drug's mechanism of action is centered on the modulation of the endocannabinoid system, where its active constituents act as agonists at Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). These receptors are integral to the regulation of the central nervous system, influencing sleep-wake cycles, emotional processing, and stress responses. S1 is currently being evaluated in clinical research settings to establish its efficacy and safety as a medical cannabis intervention for patients suffering from chronic insomnia and generalized anxiety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S1.